<DOC>
	<DOCNO>NCT00003704</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use x-rays damage tumor cell . Drugs capecitabine may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness capecitabine combination radiation therapy treat patient unresectable , residual , recurrent colorectal cancer locate pelvis .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Unresectable , Residual , Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oral capecitabine administer combination pelvic radiotherapy patient unresectable , residual , locally recurrent cancer localize pelvis . II . Determine tolerance regimen patient . III . Determine preliminary evidence therapeutic acticivity regimen patient . OUTLINE : This dose-escalation study capecitabine . Patients receive oral capecitabine twice day 7 day week 6 week concurrent radiotherapy . Radiotherapy initiate day initiation capecitabine administer 5 day week 5.5-6 week . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) reach . The MTD define dose 2 3 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A maximum 51 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma locate pelvis unresectable , incompletely resect , locally recurrent Must biopsyproven radiological progression All disease must encompassable within standard pelvic radiotherapy field No evidence metastatic disease outside plan radiotherapy field PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine clearance least 30 mL/min Other : Must maintain adequate oral nutrition ( i.e. , least 1200 calorie estimate intake per day ) No significant infection concurrent medical condition would preclude study No significant nausea vomit No malabsorption secondary shortgut syndrome , Crohn 's disease , sprue No patient 6 bowel movement per day baseline great grade 3 diarrhea patient colostomy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic cancer At least 6 month since prior adjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy Surgery : At least 21 day since prior laparotomy laparoscopic procedure without resection Other : No concurrent sorivudine chemically related analogue ( e.g. , brivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III vulvar cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>stage III penile cancer</keyword>
	<keyword>recurrent penile cancer</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
</DOC>